Navigation Links
Deadly stomach infection rising in community settings, Mayo Clinic study finds
Date:10/26/2009

ROCHESTER, Minn. Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile, (http://www.mayoclinic.org/c-difficile/) is on the rise in outpatient settings. Clostridium difficile is a serious bacteria that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. These findings were presented today at the 2009 American College of Gastroenterology (ACG) Annual Meeting in San Diego.

Clostridium difficile, often called C. difficile or "C. diff", is a bacterium that is resistant to some antibiotics and is most often contracted by the elderly in hospitals and nursing homes.

"Recent reports have shown increasing incidence and severity of C. difficile infection especially in the older population," says Darrell Pardi, M.D., Mayo Clinic gastroenterologist and senior author on the study. "Our study examines why the cases are on the rise and who is getting the infection."

In this population-based study, researchers studied 385 cases of C. difficile bacterial infection from 1991-2005 to determine how many cases were hospital-acquired versus community-acquired infections. Of the cases, 192 were hospital-acquired and 35 were residents of nursing homes. Of these hospital-acquired cases, the median age of infection was 72 years; in contrast, 158 cases were community-acquired and the median age was 50 years. Thirty-five percent of the hospital infections had a severe illness compared to 22 percent of community infections who had a severe illness.

The patients with community-acquired infection were also less likely than the hospital-acquired group to have been exposed to antibiotics before their infection. Thus, many of the community-acquired infections lacked the traditional risk factors for infection, namely recent hospitalization and exposure to antibiotics.

There were no differences between community- and hospital-acquired infections in terms of what patients were treated with (primarily metronidazole), response rates, or recurrence rates after treatment.

"We are seeing more cases of C. difficile in the community, but they tend to be less severe and in a younger population," says Dr. Pardi. "The growing incidence of C. difficile infection in both inpatient and outpatient settings could be linked to the increasing usage of antibiotics and to the possibility that C. difficile may be getting resistant to some of our newer antibiotics."

There are hundreds of kinds of bacteria found normally in the intestines. Many play beneficial roles in the body. When a patient takes an antibiotic to treat an infection, it often destroys beneficial bacteria as well as the bacteria that are causing the illness. Without enough healthy bacteria, dangerous pathogens such as C. difficile can quickly grow out of control. Once it takes hold, C. difficile can produce two virulent toxins that attack the lining of the intestine.

"Doctors have gotten better at spotting C. difficile in hospitals and nursing homes; however, now doctors and patients need to be more aware that you can get this infection as an outpatient and that a case of diarrhea or abdominal cramps at home could become serious," says Dr. Pardi.

According to the Centers for Disease Control and Prevention, each year in the United States, C. difficile is responsible for tens of thousands of diarrhea cases and at least 5,000 deaths.


'/>"/>

Contact: Amy Tieder
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Scientists Probe Sepsis Deadly Secrets
2. HIV denialists spread misinformation online -- consequences could be deadly; and more
3. Greeks get space-based help in wake of deadly fires
4. Jefferson scientists find protein may be key in developing deadly form of pancreatic cancer
5. Drug combination might offer hope for patients deadly brain tumors
6. MARCOR Responds to Deadly MRSA Outbreak
7. Common virus may help doctors treat deadly brain tumors
8. A new key to detecting deadly aortic aneurysms
9. Genes Unlock New Treatments for Deadly Melanoma
10. Northwestern exposing most deadly infectious diseases in 3-D
11. Research Lacking on Why Heart Disease is More Deadly for Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... According to an article ... account for a significant portion of hernia repairs throughout the United States. Commenting on ... Hernia Center notes that this trend has not only been expected, but it seems ...
(Date:2/12/2016)... ... 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & Bassett ... of these scholarships is to encourage applicants to pursue a degree in their field ... two parishes. , “We have available jobs in St. Landry and Evangeline Parishes ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... community at its 10th anniversary Fashion Luncheon on Monday, February 8, 2016. The ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... cycle of pharmaceutical products, garnering increased attention from all stakeholders in the development ...
(Date:2/12/2016)... ... 12, 2016 , ... As a former television executive, owner Tal Rabinowitz knows ... time to decompress, Rabinowitz found herself drawn to a casual meditation class while working ... her life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Eli Lilly and Company (NYSE: LLY ) today announced ... vitamin regimen patent would not presently be infringed by Actavis ... , Italy and Spain ... dextrose solution.  --> --> ... held that Lilly,s patent would be indirectly infringed by Actavis ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 The primary goal of this research ... on the usage of liquid biopsy. Key information the ... - Timeframe of liquid biopsy adoption amidst future users ... organization type - Sample inflow to conduct liquid biopsy ... serum, and so on. - Correlation analysis of sample ...
Breaking Medicine Technology: